These data demonstrated that CD8 T cells from TCF-1 cKO mice may maintain anti-tumor responses by killing the target cells with an NKG2D-mediated mechanism, and by persistent upregulation of Granzyme B expression [74, 75]. This evidence concerns the gene KLRK1 and neoplasm.